256 related articles for article (PubMed ID: 9816166)
21. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice.
Benhar I; Reiter Y; Pai LH; Pastan I
Int J Cancer; 1995 Jul; 62(3):351-5. PubMed ID: 7628878
[TBL] [Abstract][Full Text] [Related]
22. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
23. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
25. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.
Bera TK; Onda M; Brinkmann U; Pastan I
J Mol Biol; 1998 Aug; 281(3):475-83. PubMed ID: 9698563
[TBL] [Abstract][Full Text] [Related]
26. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
[TBL] [Abstract][Full Text] [Related]
27. [New type recombinant antibody fragment scFv multimer and cancer targeting].
Guo J; Cai M
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Jun; 20(2):361-5. PubMed ID: 12856620
[TBL] [Abstract][Full Text] [Related]
28. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.
Shinohara H; Morita S; Kawai M; Miyamoto A; Sonoda T; Pastan I; Tanigawa N
J Surg Res; 2002 Feb; 102(2):169-77. PubMed ID: 11796015
[TBL] [Abstract][Full Text] [Related]
29. Phage display of disulfide-stabilized Fv fragments.
Brinkmann U; Chowdhury PS; Roscoe DM; Pastan I
J Immunol Methods; 1995 May; 182(1):41-50. PubMed ID: 7769243
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
31. Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain.
Arndt KM; Müller KM; Plückthun A
J Mol Biol; 2001 Sep; 312(1):221-8. PubMed ID: 11545598
[TBL] [Abstract][Full Text] [Related]
32. A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs.
Rajagopal V; Pastan I; Kreitman RJ
Protein Eng; 1997 Dec; 10(12):1453-9. PubMed ID: 9543007
[TBL] [Abstract][Full Text] [Related]
33. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.
Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P
Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
Hassan R; Lerner MR; Benbrook D; Lightfoot SA; Brackett DJ; Wang QC; Pastan I
Clin Cancer Res; 2002 Nov; 8(11):3520-6. PubMed ID: 12429643
[TBL] [Abstract][Full Text] [Related]
35. Construction of a functional disulfide-stabilized TCR Fv indicates that antibody and TCR Fv frameworks are very similar in structure.
Reiter Y; Kurucz I; Brinkmann U; Jung SH; Lee B; Segal DM; Pastan I
Immunity; 1995 Mar; 2(3):281-7. PubMed ID: 7697545
[TBL] [Abstract][Full Text] [Related]
36. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Albrecht H; Denardo GL; Denardo SJ
J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
[TBL] [Abstract][Full Text] [Related]
37. Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: conformational influence of an engineered disulfide bond.
Almog O; Benhar I; Vasmatzis G; Tordova M; Lee B; Pastan I; Gilliland GL
Proteins; 1998 May; 31(2):128-38. PubMed ID: 9593187
[TBL] [Abstract][Full Text] [Related]
38. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
39. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
40. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
